Clinical efficacy of marbofloxacin in dogs and cats diagnosed with lower urinary tract disorders

• Autorzy: Dokuzeyluk B. , Celik B. , Sigirci B.D. , Kahraman B.B. , Saka S.U. , Kayar A. , Ak S. , Or M/.E.
• Języki publikacji: EN

Abstrakty

EN

Marbofloxacin is one of the fluoroquinolones developed exclusively for veterinary medicine. The primary aim of the present study is to identify and assess evidence for marbofloxacin’s clinical efficacy in the treatment of urinary tract infections in small animal practice. The study included 118 dogs and 123 cats that were referred to the Internal Medicine Department with lower urinary tract symptoms. We excluded animals that had received antimicrobial or anti-inflammatory therapy in the previous 15 days. Diagnosis was confirmed by clinical findings, urinalysis, and imaging. Rectal temperature, appetite, urinary signs, and abdominal pain were monitored during two visits (day 0 and 14). The timetable depended on the diagnosis of the following: two urinalyses, two bacterial examinations, and antibacterial susceptibility testing were performed for each case. Bacterial UTI were confirmed in 36 dogs and 28 cats. Urine samples were collected on day 0, which demonstrated the presence of various bacteria, with a marked predominance of P. mirabilis and coagulase-positive Staphylococci in canine and feline urine samples, respectively. Antimicrobial susceptibility test results revealed 25 (65.7%) of dog isolates and 24 (85.7%) of cat isolates were susceptible to marbofloxacin. Treatment of UTIs is generally challenging for the small animal practitioner. Because of the need for long-term antimicrobials, bacterial culture and susceptibility tests are especially important for successful treatment. Marbofloxacin can be part of an effective treatment of UTIs in dogs and cats.

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2019
• Tom: 75
• Numer: 09
• Opis fizyczny: p.549-552, fig.,ref.

Twórcy

autor

Dokuzeyluk B.

• Department of Internal Medicine, Faculty of Veterinary Medicine, Istanbul University-Cerrahpasa, 34320, Avcılar-Istanbul, Turkey

autor

Celik B.

• Department of Microbiology, Faculty of Veterinary Medicine, Istanbul University-Cerrahpasa, 34320, Avcılar-Istanbul, Turkey

autor

Sigirci B.D.

• Department of Microbiology, Faculty of Veterinary Medicine, Istanbul University-Cerrahpasa, 34320, Avcılar-Istanbul, Turkey

autor

Kahraman B.B.

• Department of Microbiology, Faculty of Veterinary Medicine, Istanbul University-Cerrahpasa, 34320, Avcılar-Istanbul, Turkey

autor

Saka S.U.

• Department of Internal Medicine, Faculty of Veterinary Medicine, Istanbul University-Cerrahpasa, 34320, Avcılar-Istanbul, Turkey

autor

Kayar A.

• Department of Internal Medicine, Faculty of Veterinary Medicine, Istanbul University-Cerrahpasa, 34320, Avcılar-Istanbul, Turkey

autor

Ak S.

• Department of Microbiology, Faculty of Veterinary Medicine, Istanbul University-Cerrahpasa, 34320, Avcılar-Istanbul, Turkey

autor

Or M/.E.

• Department of Internal Medicine, Faculty of Veterinary Medicine, Istanbul University-Cerrahpasa, 34320, Avcılar-Istanbul, Turkey

Bibliografia

• Apley M. B., Brown S. D., Gray J. T., Heine H., Hunter R. P., Mevius D. J., Papich M. G., Silley P., Zurenko G. E.: Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals, approved standard-third edition. CLSI document M31-A3. Clinical and Laboratory Standards Institute, Wayne P. A., USA 2008.
• Chopra S., Galande A.: A fluoroquinolone-resistant Acinetobacter baumannii without the quinolone resistance-determining region mutations. J. Antimicrob. Chemother. 2011, 66, 2668-2670.
• CLSI document M02-A10, CLSI. 2009.
• Cotard J., Gruet P., Pechereau D., Moreau P., Thomas E., Deleforge J.: Comparative study of marbofloxacin and amoxicillinclavulanic acid in the treatment of urinary tract infections in dogs. J. Small Anim. Pract. 1995, 36, 349-353.
• Freitag T., Squires R. A., Schmid J., Elliott J., Rycroft A. N.: Antibiotic sensitivity profiles do not reliably distinguish relapsing or persisting infections from reinfections in cats with chronic renal failure and multiple diagnoses of Escherichia coli urinary tract infection. J. Vet. Intern. Med. 2006, 20, 245-249.
• Gebru E., Choi M. J., Lee S. J., Damte D., Park S. C.: Mutant-prevention concentration and mechanism of resistance in clinical isolates and enrofloxacin/marbofloxacin-selected mutants of Escherichia coli of canine origin. J. Med. Microbiol. 2011, 60, 1512-1522.
• Gerber B., Boretti F. S., Kley S., Laluha P., Muller C. N., Sieber S., Unterer M., Wenger M., Fluckiger Glaus T., Reusch C. E.: Evaluation of clinical signs and causes of lower urinary tract disease in European cats. J. Small Anim. Pract. 2005, 46, 571-577.
• Ihrke P. J., Papich M. G., Demanuelle T. C.: The use of fluoroquinolones in veterinary dermatology. Vet. Dermatol. 1999, 10, 193-204.
• Jessen L. R., Sorensen T. M., Bjornvad C. R., Nielsen S. S., Guardabassi L.: Effect of antibiotic treatment in canine and feline urinary tract infections: a systematic review. Vet. J. 2015, 203, 270-277.
• Lefebvre H. P., Schneider M., Dupouy V., Laroute V., Costes G., Delesalle L., Toutain P. L.: Effect of experimental renal impairment on disposition of marbofloxacin and its metabolites in the dog. J. Vet. Pharmacol. Ther. 1998, 21, 453-461.
• Litster A., Moss S., Platell J., Trott D. J.: Occult bacterial lower urinary tract infections in cats-urinalysis and culture findings. Vet. Microbiol. 2009, 136, 130-134.
• Litster A., Thompson M., Moss S., Trott D.: Feline bacterial urinary tract infections: An update on an evolving clinical problem. Vet. J. 2011, 187, 18-22.
• Marbofloxacin reference book:1999, Vetoquinol
• Olin S. J., Bartges J. W.: Urinary tract infections: treatment/comparative therapeutics. Vet. Clin. North Am. Small Anim. Pract. 2015, 45, 721-746.
• Pallo-Zimmerman L. M., Byron J. K., Graves T. K.: Fluoroquinolones: then and now. Compend. Contin. Educ. Vet. 2010, 32, E1-9.
• Paradis M., Abbey L., Baker B., Coyne M., Hannigan M., Joffe D., Pukay B., Trettien A., Waisglass S., Wellington J.: Evaluation of the clinical efficacy of marbofloxacin (Zeniquin) tablets for the treatment of canine pyoderma: an open clinical trial. Vet. Dermatol. 2001, 12, 163-169.
• Passmore C. A., Sherington J., Stegemann M. R.: Efficacy and safety of cefovecin for the treatment of urinary tract infections in cats. J. Small Anim. Pract. 2008, 49, 295-301.
• Quinn P. J., Markey B. K., Leonard F. C., FitzPatrick E. S., Fanning S., Hartigan P.: Veterinary Microbiology and Microbial Disease. John Wiley&Sons, first edition, 1994.
• Quinn P. J., Markey B. K., Leonard F. C., FitzPatrick E. S., Fanning S., Hartigan P.: Veterinary Microbiology and Microbial Disease. John Wiley&Sons, fourth edition, 2002.
• Tucak P.: Plumb’s Veterinary Drug Handbook. DC Plumb, Wiley-Blackwell 2015, 1296.
• Yohannes S., Awji E. G., Lee S. J., Park S. C.: Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of marbofloxacin after intravenous and intramuscular administration in beagle dogs. Xenobiotica 2015, 45, 264-269.

Identyfikatory

DOI

10.21521/mw.6269